Medtronic reports second quarter fiscal 2024 financial results

 
 

  Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year guidance  

 

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023 .

 

   Key Highlights   

 
  • Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic

    •  
  • GAAP diluted earnings per share (EPS) of $0.68 ; non-GAAP diluted EPS of $1.25  

    •  
  • Underlying business fundamentals are strong with broad-based, diversified growth coming from multiple businesses and geographies

    •  
  • Company increases FY24 organic revenue growth and EPS guidance

    •  
  • Received U.S. FDA approval for Aurora EV-ICD™ system and Symplicity Spyral™ renal denervation (RDN) system; CE Mark for Evolut™ FX TAVR system, Simplera™ standalone CGM, and PulseSelect™ pulsed field ablation (PFA) system
    •  

   Financial Results
  Medtronic reported Q2 worldwide revenue of $7.984 billion , an increase of 5.3% as reported and 5.0% on an organic basis. The company's organic revenue results reflect continued broad strength across businesses and geographies benefiting from durable fundamentals. The organic revenue growth comparison excludes:

 
  • Revenue and the associated impact from foreign currency translation reported as Other, stemming from business separations, including Renal Care Solutions and ongoing manufacturing agreements with Cardinal Health from the divestiture of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency; and

    •  
  • The favorable impact from foreign currency translation of $86 million on the remaining segments.
    •  

As reported, Q2 GAAP net income and diluted EPS were $909 million and $0.68 , respectively, both representing increases of 113%. As detailed in the financial schedules included at the end of this release, Q2 non-GAAP net income of $1.667 billion decreased 3% and non-GAAP diluted EPS of $1.25 decreased 4%. Included in non-GAAP diluted EPS was an 8 cent , or 6%, unfavorable impact from foreign currency translation.

 

"We're delivering a track record of durable, mid-single digit revenue growth. The underlying fundamentals are strong, and our solid results were broad-based across our businesses and geographies," said Geoff Martha , Medtronic chairman and chief executive officer. "We're bringing game changing innovation to market, with numerous recent regulatory approvals and major product launches, which give us confidence in our ability to continue delivering dependable growth."

 

   Cardiovascular Portfolio
  The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $2.923 billion increased 5.9% as reported and 4.8% organic, with a high-single digit organic increase in SHA and mid-single digit organic increases in CRHF and CPV.

 
  • CRHF results driven by high-single digit growth in Cardiac Pacing Therapies, including low-double digit growth in Micra™ transcatheter pacing systems; Cardiovascular Diagnostics grew high-single digits and Cardiac Ablation Solutions grew mid-single digits

    •  
  • SHA drove high-single digit growth in Aortic and Cardiac Surgery; Structural Heart (TAVR) grew mid-single digits on the continued adoption of Evolut™ FX in the U.S. & Japan  

    •  
  • CPV results driven by mid-single digit growth in Coronary on the continued strength of the Onyx Frontier™ drug-eluting stent and low-single digit growth in Peripheral Vascular Health on mid-teens growth in drug-coated balloons

    •  
  • Received U.S. FDA approval for Aurora EV-ICD™ system and Symplicity Spyral™ RDN system; CE Mark for Evolut™ FX transcatheter aortic valve implantation system and PulseSelect™ pulsed field ablation (PFA) system

    •  
  • Presented four-year results from Evolut Low Risk Trial at the 2023 TCT conference showing the Evolut™ TAVR system demonstrated exceptional outcomes with sustained valve performance, proven by significantly better hemodynamics, low thrombosis rates, and lower and diverging rates of all-cause mortality or disabling stroke than surgical aortic valve replacement (SAVR) at four years
    •  

   Neuroscience Portfolio
  The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.288 billion increased 4.7% as reported and 4.2% organic, with a high-single digit organic increase in CST and low-single digit organic increases in Specialty Therapies and Neuromodulation.

 
  • CST delivered high-single digit Core Spine growth on implant pull-through fueled by continued adoption of the AiBLE™ ecosystem; Neurosurgery grew mid-single digits on strong sales of StealthStation™ navigation and O-arm™ imaging systems

    •  
  • Specialty Therapies results driven by mid-single digit growth in Neurovascular on strength in flow diversion and low-single digit growth in ENT and Pelvic Health; excluding a product line divestiture, Pelvic Health grew mid-single digits

    •  
  • Neuromodulation drove mid-single digit growth in Targeted Drug Delivery and low-single digit growth in Pain Stim
    •  

   Medical Surgical Portfolio
  The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Patient Monitoring & Respiratory Interventions (PMRI) divisions. Revenue of $2.142 billion increased 7.0% as reported and 5.6% organic, with a high-single digit organic increase in SE and low-single digit organic increase in PMRI.

 
  • SE results driven by low-double digit growth in General Surgical Technologies, mid-single digit growth in Advanced Surgical Technologies, and low-double digit growth in Endoscopy

    •  
  • SE also drove installed base growth of the Hugo™ robotic-assisted surgery (RAS) system; received Investigational Device Exemption (IDE) from U.S. FDA to begin the U.S. clinical trial for Hugo™ RAS system for Hernia procedures

    •  
  • PMRI results driven by low-single digit growth in Patient Monitoring, with double-digit growth in Nellcor™ pulse oximetry monitor sales; Respiratory Interventions results were flat, with high-single digit growth in Airways offset by decreases in Ventilator sales
    •  

   Diabetes
  Diabetes revenue of $610 million increased 9.7% as reported and 6.7% organic.

 
  • Non-U.S. Developed Markets grew mid-teens on continued MiniMed™ 780G system adoption and increased CGM attachment rates on the strength of the Guardian™ 4 sensor

    •  
  • First full quarter of the U.S. launch of MiniMed™ 780G system resulted in low-thirties sequential growth in U.S. Diabetes pump revenue; overall, U.S. Diabetes declined mid-single digits year-over-year on customer attrition versus the prior year; customer base increased sequentially

    •  
  • Received CE Mark and began phased launch for Simplera™ standalone CGM
    •  

   Guidance
  The company today raised its FY24 revenue growth and EPS guidance.

 

The company increased its FY24 organic revenue growth guidance to 4.75% versus the prior 4.5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue related to certain businesses reported as Other. Including Other revenue and the impact of foreign currency, if foreign currency exchange rates as of the beginning of November hold, FY24 revenue growth on a reported basis would be approximately 2.6%.

 

The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.08 to $5.16 to the new range of $5.13 to $5.19 , a 4 cent increase at the midpoint. Given the change in foreign currency exchange rates over the past quarter, the foreign exchange impact on FY24 diluted non-GAAP EPS is now estimated to be 2 cents more unfavorable in the second half and is estimated to be a 6% unfavorable impact for the full year.

 

"Overall, it was another good quarter as we delivered revenue, margins, and earnings ahead of expectations. Combining our second quarter outperformance with our updated tax and foreign currency estimates, we're raising our full year organic revenue growth and EPS guidance," said Karen Parkhill , Medtronic EVP & chief financial officer. "Based on the changes we've made to our operating model, incentives, and capital allocation, among other drivers, we've positioned the company to deliver consistent mid-single digit growth on the top line. As we move ahead, translating this durable revenue growth into durable earnings power remains a top priority."

 

   Video Webcast Information
  Medtronic will host a video webcast today, November 21 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .

 

Medtronic plans to report its FY24 third and fourth quarter results on Tuesday, February 20, 2024 , and Thursday, May 23, 2024 , respectively. Confirmation and additional details will be provided closer to the specific event.

 

   Financial Schedules
  The second quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the second quarter earnings presentation, click here .

 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 

   MEDTRONIC PLC   

 
 

   WORLD WIDE REVENUE (1)   

 
 

  (Unaudited)  

 
 
 
 

   SECOND QUARTER   

 		 
 
 

   YEAR-TO-DATE   

 
 
 

   REPORTED   

 		 
 
 
 

   ORGANIC   

 		 
 
 

   REPORTED   

 		 
 
 
 

   ORGANIC   

 
 

   (in millions)   

 		 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Currency
Impact (2)  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 		 
 
 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Currency
Impact (2)  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 
 

   Cardiovascular   

 		 

   $    2,923   

 		 
 

   $    2,759   

 		 
 

   5.9 %   

 		 
 

   $        31   

 		 
 

   $    2,892   

 		 
 

   $    2,759   

 		 
 

   4.8 %   

 		 
 
 

   $    5,773   

 		 
 

   $    5,459   

 		 
 

   5.8 %   

 		 
 

   $        12   

 		 
 

   $    5,761   

 		 
 

   $    5,459   

 		 
 

   5.5 %   

 
 

  Cardiac Rhythm & Heart Failure  

 		 

  1,492  

 		 
 

  1,417  

 		 
 

  5.3  

 		 
 

  18  

 		 
 

  1,474  

 		 
 

  1,417  

 		 
 

  4.0  

 		 
 
 

  2,938  

 		 
 

  2,798  

 		 
 

  5.0  

 		 
 

  11  

 		 
 

  2,927  

 		 
 

  2,798  

 		 
 

  4.6  

 
 

  Structural Heart & Aortic  

 		 

  819  

 		 
 

  757  

 		 
 

  8.2  

 		 
 

  11  

 		 
 

  808  

 		 
 

  757  

 		 
 

  6.7  

 		 
 
 

  1,633  

 		 
 

  1,499  

 		 
 

  8.9  

 		 
 

  6  

 		 
 

  1,627  

 		 
 

  1,499  

 		 
 

  8.5  

 
 

  Coronary & Peripheral Vascular  

 		 

  613  

 		 
 

  584  

 		 
 

  5.0  

 		 
 

  2  

 		 
 

  611  

 		 
 

  584  

 		 
 

  4.6  

 		 
 
 

  1,202  

 		 
 

  1,163  

 		 
 

  3.4  

 		 
 

  (5)  

 		 
 

  1,207  

 		 
 

  1,163  

 		 
 

  3.8  

 
 

   Neuroscience   

 		 

   2,288   

 		 
 

   2,186   

 		 
 

   4.7   

 		 
 

   10   

 		 
 

   2,278   

 		 
 

   2,186   

 		 
 

   4.2   

 		 
 
 

   4,506   

 		 
 

   4,301   

 		 
 

   4.8   

 		 
 

   (5)   

 		 
 

   4,511   

 		 
 

   4,301   

 		 
 

   4.9   

 
 

  Cranial & Spinal Technologies  

 		 

  1,157  

 		 
 

  1,081  

 		 
 

  7.0  

 		 
 

  4  

 		 
 

  1,153  

 		 
 

  1,081  

 		 
 

  6.7  

 		 
 
 

  2,260  

 		 
 

  2,124  

 		 
 

  6.4  

 		 
 

  (3)  

 		 
 

  2,263  

 		 
 

  2,124  

 		 
 

  6.5  

 
 

  Specialty Therapies  

 		 

  705  

 		 
 

  686  

 		 
 

  2.8  

 		 
 

  1  

 		 
 

  704  

 		 
 

  686  

 		 
 

  2.6  

 		 
 
 

  1,400  

 		 
 

  1,353  

 		 
 

  3.5  

 		 
 

  (7)  

 		 
 

  1,407  

 		 
 

  1,353  

 		 
 

  4.0  

 
 

  Neuromodulation  

 		 

  426  

 		 
 

  419  

 		 
 

  1.7  

 		 
 

  5  

 		 
 

  421  

 		 
 

  419  

 		 
 

  0.5  

 		 
 
 

  846  

 		 
 

  824  

 		 
 

  2.7  

 		 
 

  5  

 		 
 

  841  

 		 
 

  824  

 		 
 

  2.1  

 
 

   Medical Surgical   

 		 

   2,142   

 		 
 

   2,002   

 		 
 

   7.0   

 		 
 

   27   

 		 
 

   2,115   

 		 
 

   2,002   

 		 
 

   5.6   

 		 
 
 

   4,181   

 		 
 

   3,935   

 		 
 

   6.3   

 		 
 

   16   

 		 
 

   4,165   

 		 
 

   3,935   

 		 
 

   5.8   

 
 

  Surgical & Endoscopy  

 		 

  1,641  

 		 
 

  1,513  

 		 
 

  8.5  

 		 
 

  25  

 		 
 

  1,616  

 		 
 

  1,513  

 		 
 

  6.8  

 		 
 
 

  3,187  

 		 
 

  2,968  

 		 
 

  7.4  

 		 
 

  17  

 		 
 

  3,170  

 		 
 

  2,968  

 		 
 

  6.8  

 
 

  Patient Monitoring & Respiratory Interventions  

 		 

  501  

 		 
 

  489  

 		 
 

  2.5  

 		 
 

  3  

 		 
 

  498  

 		 
 

  489  

 		 
 

  1.8  

 		 
 
 

  994  

 		 
 

  967  

 		 
 

  2.8  

 		 
 

  (2)  

 		 
 

  996  

 		 
 

  967  

 		 
 

  3.0  

 
 

   Diabetes   

 		 

   610   

 		 
 

   556   

 		 
 

   9.7   

 		 
 

   17   

 		 
 

   593   

 		 
 

   556   

 		 
 

   6.7   

 		 
 
 

   1,189   

 		 
 

   1,098   

 		 
 

   8.3   

 		 
 

   20   

 		 
 

   1,169   

 		 
 

   1,098   

 		 
 

   6.5   

 
 

   Other (3)   

 		 

   22   

 		 
 

   82   

 		 
 

   (73.2)   

 		 
 

   (1)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 		 
 
 

   37   

 		 
 

   162   

 		 
 

   (77.2)   

 		 
 

   (5)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 
 

   TOTAL   

 		 

   $    7,984   

 		 
 

   $    7,585   

 		 
 

   5.3 %   

 		 
 

   $        85   

 		 
 

   $    7,876   

 		 
 

   $    7,503   

 		 
 

   5.0 %   

 		 
 
 

   $  15,686   

 		 
 

   $  14,955   

 		 
 

   4.9 %   

 		 
 

   $        38   

 		 
 

   $  15,605   

 		 
 

   $  14,793   

 		 
 

   5.5 %   

 
 
 
 
        
 
 
 

  (1)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 

  (2)  

 		 

  The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.  

 
 

  (3)  

 		 

  Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                         
 

   MEDTRONIC PLC   

 
 

   U.S. (1)(2) REVENUE   

 
 

  (Unaudited)  

 
 
 
 

   SECOND QUARTER   

 		 
 
 

   YEAR-TO-DATE   

 
 
 

   REPORTED   

 		 
 

   ORGANIC   

 		 
 
 

   REPORTED   

 		 
 

   ORGANIC   

 
 

   (in millions)   

 		 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 		 
 
 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 
 

   Cardiovascular   

 		 

   $    1,427   

 		 
 

   $    1,410   

 		 
 

   1.2 %   

 		 
 

   $    1,427   

 		 
 

   $    1,410   

 		 
 

   1.2 %   

 		 
 
 

   $    2,776   

 		 
 

   $    2,696   

 		 
 

   3.0 %   

 		 
 

   $    2,776   

 		 
 

   $    2,696   

 		 
 

   3.0 %   

 
 

  Cardiac Rhythm & Heart Failure  

 		 

  782  

 		 
 

  776  

 		 
 

  0.8  

 		 
 

  782  

 		 
 

  776  

 		 
 

  0.8  

 		 
 
 

  1,502  

 		 
 

  1,481  

 		 
 

  1.4  

 		 
 

  1,502  

 		 
 

  1,481  

 		 
 

  1.4  

 
 

  Structural Heart & Aortic  

 		 

  367  

 		 
 

  348  

 		 
 

  5.5  

 		 
 

  367  

 		 
 

  348  

 		 
 

  5.5  

 		 
 
 

  724  

 		 
 

  660  

 		 
 

  9.7  

 		 
 

  724  

 		 
 

  660  

 		 
 

  9.7  

 
 

  Coronary & Peripheral Vascular  

 		 

  278  

 		 
 

  286  

 		 
 

  (2.8)  

 		 
 

  278  

 		 
 

  286  

 		 
 

  (2.8)  

 		 
 
 

  550  

 		 
 

  555  

 		 
 

  (0.9)  

 		 
 

  550  

 		 
 

  555  

 		 
 

  (0.9)  

 
 

   Neuroscience   

 		 

   1,560   

 		 
 

   1,512   

 		 
 

   3.2   

 		 
 

   1,560   

 		 
 

   1,512   

 		 
 

   3.2   

 		 
 
 

   3,057   

 		 
 

   2,931   

 		 
 

   4.3   

 		 
 

   3,057   

 		 
 

   2,931   

 		 
 

   4.3   

 
 

  Cranial & Spinal Technologies  

 		 

  863  

 		 
 

  817  

 		 
 

  5.6  

 		 
 

  863  

 		 
 

  817  

 		 
 

  5.6  

 		 
 
 

  1,685  

 		 
 

  1,580  

 		 
 

  6.6  

 		 
 

  1,685  

 		 
 

  1,580  

 		 
 

  6.6  

 
 

  Specialty Therapies  

 		 

  403  

 		 
 

  403  

 		 
 

  —  

 		 
 

  403  

 		 
 

  403  

 		 
 

  —  

 		 
 
 

  795  

 		 
 

  784  

 		 
 

  1.4  

 		 
 

  795  

 		 
 

  784  

 		 
 

  1.4  

 
 

  Neuromodulation  

 		 

  293  

 		 
 

  291  

 		 
 

  0.7  

 		 
 

  293  

 		 
 

  291  

 		 
 

  0.7  

 		 
 
 

  577  

 		 
 

  567  

 		 
 

  1.8  

 		 
 

  577  

 		 
 

  567  

 		 
 

  1.8  

 
 

   Medical Surgical   

 		 

   963   

 		 
 

   895   

 		 
 

   7.6   

 		 
 

   963   

 		 
 

   895   

 		 
 

   7.6   

 		 
 
 

   1,845   

 		 
 

   1,726   

 		 
 

   6.9   

 		 
 

   1,845   

 		 
 

   1,726   

 		 
 

   6.9   

 
 

  Surgical & Endoscopy  

 		 

  688  

 		 
 

  633  

 		 
 

  8.7  

 		 
 

  688  

 		 
 

  633  

 		 
 

  8.7  

 		 
 
 

  1,308  

 		 
 

  1,214  

 		 
 

  7.7  

 		 
 

  1,308  

 		 
 

  1,214  

 		 
 

  7.7  

 
 

  Patient Monitoring & Respiratory Interventions  

 		 

  275  

 		 
 

  262  

 		 
 

  5.0  

 		 
 

  275  

 		 
 

  262  

 		 
 

  5.0  

 		 
 
 

  537  

 		 
 

  512  

 		 
 

  4.9  

 		 
 

  537  

 		 
 

  512  

 		 
 

  4.9  

 
 

   Diabetes   

 		 

   217   

 		 
 

   228   

 		 
 

   (4.8)   

 		 
 

   217   

 		 
 

   228   

 		 
 

   (4.8)   

 		 
 
 

   405   

 		 
 

   434   

 		 
 

   (6.7)   

 		 
 

   405   

 		 
 

   434   

 		 
 

   (6.7)   

 
 

   Other (3)   

 		 

   8   

 		 
 

   23   

 		 
 

   (65.2)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 		 
 
 

   16   

 		 
 

   49   

 		 
 

   (67.3)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 
 

   TOTAL   

 		 

   $    4,175   

 		 
 

   $    4,069   

 		 
 

   2.6 %   

 		 
 

   $    4,167   

 		 
 

   $    4,046   

 		 
 

   3.0 %   

 		 
 
 

   $    8,099   

 		 
 

   $    7,835   

 		 
 

   3.4 %   

 		 
 

   $    8,083   

 		 
 

   $    7,787   

 		 
 

   3.8 %   

 
 
 
 
        
 
 
 

  (1)  

 		 

  U.S. includes the United States and U.S. territories.  

 
 

  (2)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 

  (3)  

 		 

  Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 

   MEDTRONIC PLC   

 
 

   WORLD WIDE REVENUE: GEOGRAPHIC (1)(2)   

 
 

  (Unaudited)  

 
 
 
 

   SECOND QUARTER   

 		 
 
 

   YEAR-TO-DATE   

 
 
 

   REPORTED   

 		 
 
 
 

   ORGANIC   

 		 
 
 

   REPORTED   

 		 
 
 
 

   ORGANIC   

 
 

   (in millions)   

 		 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Currency
Impact (3)  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 		 
 
 

  FY24  

 		 
 

  FY23  

 		 
 

  Growth  

 		 
 

  Currency
Impact (3)  

 		 
 

  Adjusted
FY24  

 		 
 

  Adjusted
FY23  

 		 
 

  Growth  

 
 

  U.S.  

 		 

  $    1,427  

 		 
 

  $    1,410  

 		 
 

  1.2 %  

 		 
 

  $         —  

 		 
 

  $    1,427  

 		 
 

  $    1,410  

 		 
 

  1.2 %  

 		 
 
 

  $    2,776  

 		 
 

  $    2,696  

 		 
 

  3.0 %  

 		 
 

  $         —  

 		 
 

  $    2,776  

 		 
 

  $     2,696  

 		 
 

  3.0 %  

 
 

  Non-U.S. Developed  

 		 

  912  

 		 
 

  802  

 		 
 

  13.7  

 		 
 

  43  

 		 
 

  869  

 		 
 

  802  

 		 
 

  8.4  

 		 
 
 

  1,869  

 		 
 

  1,694  

 		 
 

  10.3  

 		 
 

  45  

 		 
 

  1,824  

 		 
 

  1,694  

 		 
 

  7.7  

 
 

  Emerging Markets  

 		 

  584  

 		 
 

  546  

 		 
 

  7.0  

 		 
 

  (12)  

 		 
 

  596  

 		 
 

  546  

 		 
 

  9.2  

 		 
 
 

  1,128  

 		 
 

  1,070  

 		 
 

  5.4  

 		 
 

  (33)  

 		 
 

  1,161  

 		 
 

  1,070  

 		 
 

  8.5  

 
 

   Cardiovascular   

 		 

   2,923   

 		 
 

   2,759   

 		 
 

   5.9   

 		 
 

   31   

 		 
 

   2,892   

 		 
 

   2,759   

 		 
 

   4.8   

 		 
 
 

   5,773   

 		 
 

   5,459   

 		 
 

   5.8   

 		 
 

   12   

 		 
 

   5,761   

 		 
 

   5,459   

 		 
 

   5.5   

 
 

  U.S.  

 		 

  1,560  

 		 
 

  1,512  

 		 
 

  3.2  

 		 
 

  —  

 		 
 

  1,560  

 		 
 

  1,512  

 		 
 

  3.2  

 		 
 
 

  3,057  

 		 
 

  2,931  

 		 
 

  4.3  

 		 
 

  —  

 		 
 

  3,057  

 		 
 

  2,931  

 		 
 

  4.3  

 
 

  Non-U.S. Developed  

 		 

  399  

 		 
 

  382  

 		 
 

  4.5  

 		 
 

  14  

 		 
 

  385  

 		 
 

  382  

 		 
 

  0.8  

 		 
 
 

  815  

 		 
 

  788  

 		 
 

  3.4  

 		 
 

  10  

 		 
 

  805  

 		 
 

  788  

 		 
 

  2.2  

 
 

  Emerging Markets  

 		 

  329  

 		 
 

  292  

 		 
 

  12.7  

 		 
 

  (4)  

 		 
 

  333  

 		 
 

  292  

 		 
 

  14.0  

 		 
 
 

  634  

 		 
 

  582  

 		 
 

  8.9  

 		 
 

  (15)  

 		 
 

  649  

 		 
 

  582  

 		 
 

  11.5  

 
 

   Neuroscience   

 		 

   2,288   

 		 
 

   2,186   

 		 
 

   4.7   

 		 
 

   10   

 		 
 

   2,278   

 		 
 

   2,186   

 		 
 

   4.2   

 		 
 
 

   4,506   

 		 
 

   4,301   

 		 
 

   4.8   

 		 
 

   (5)   

 		 
 

   4,511   

 		 
 

   4,301   

 		 
 

   4.9   

 
 

  U.S.  

 		 

  963  

 		 
 

  895  

 		 
 

  7.6  

 		 
 

  —  

 		 
 

  963  

 		 
 

  895  

 		 
 

  7.6  

 		 
 
 

  1,845  

 		 
 

  1,726  

 		 
 

  6.9  

 		 
 

  —  

 		 
 

  1,845  

 		 
 

  1,726  

 		 
 

  6.9  

 
 

  Non-U.S. Developed  

 		 

  740  

 		 
 

  685  

 		 
 

  8.0  

 		 
 

  27  

 		 
 

  713  

 		 
 

  685  

 		 
 

  4.1  

 		 
 
 

  1,512  

 		 
 

  1,420  

 		 
 

  6.5  

 		 
 

  21  

 		 
 

  1,491  

 		 
 

  1,420  

 		 
 

  5.0  

 
 

  Emerging Markets  

 		 

  438  

 		 
 

  421  

 		 
 

  4.0  

 		 
 

  1  

 		 
 

  437  

 		 
 

  421  

 		 
 

  3.8  

 		 
 
 

  824  

 		 
 

  789  

 		 
 

  4.4  

 		 
 

  (5)  

 		 
 

  829  

 		 
 

  789  

 		 
 

  5.1  

 
 

   Medical Surgical   

 		 

   2,142   

 		 
 

   2,002   

 		 
 

   7.0   

 		 
 

   27   

 		 
 

   2,115   

 		 
 

   2,002   

 		 
 

   5.6   

 		 
 
 

   4,181   

 		 
 

   3,935   

 		 
 

   6.3   

 		 
 

   16   

 		 
 

   4,165   

 		 
 

   3,935   

 		 
 

   5.8   

 
 

  U.S.  

 		 

  217  

 		 
 

  228  

 		 
 

  (4.8)  

 		 
 

  —  

 		 
 

  217  

 		 
 

  228  

 		 
 

  (4.8)  

 		 
 
 

  405  

 		 
 

  434  

 		 
 

  (6.7)  

 		 
 

  —  

 		 
 

  405  

 		 
 

  434  

 		 
 

  (6.7)  

 
 

  Non-U.S. Developed  

 		 

  310  

 		 
 

  254  

 		 
 

  22.0  

 		 
 

  18  

 		 
 

  292  

 		 
 

  254  

 		 
 

  15.0  

 		 
 
 

  625  

 		 
 

  518  

 		 
 

  20.7  

 		 
 

  22  

 		 
 

  603  

 		 
 

  518  

 		 
 

  16.4  

 
 

  Emerging Markets  

 		 

  84  

 		 
 

  74  

 		 
 

  13.5  

 		 
 

  (1)  

 		 
 

  85  

 		 
 

  74  

 		 
 

  14.9  

 		 
 
 

  159  

 		 
 

  145  

 		 
 

  9.7  

 		 
 

  (3)  

 		 
 

  162  

 		 
 

  145  

 		 
 

  11.7  

 
 

   Diabetes   

 		 

   610   

 		 
 

   556   

 		 
 

   9.7   

 		 
 

   17   

 		 
 

   593   

 		 
 

   556   

 		 
 

   6.7   

 		 
 
 

   1,189   

 		 
 

   1,098   

 		 
 

   8.3   

 		 
 

   20   

 		 
 

   1,169   

 		 
 

   1,098   

 		 
 

   6.5   

 
 

  U.S.  

 		 

  8  

 		 
 

  23  

 		 
 

  (65.2)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 
 

  16  

 		 
 

  49  

 		 
 

  (67.3)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

  Non-U.S. Developed  

 		 

  7  

 		 
 

  33  

 		 
 

  (78.8)  

 		 
 

  (1)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 
 

  12  

 		 
 

  65  

 		 
 

  (81.5)  

 		 
 

  (2)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

  Emerging Markets  

 		 

  7  

 		 
 

  25  

 		 
 

  (72.0)  

 		 
 

  (1)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 
 

  10  

 		 
 

  48  

 		 
 

  (79.2)  

 		 
 

  (2)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

   Other (4)   

 		 

   22   

 		 
 

   82   

 		 
 

   (73.2)   

 		 
 

   (1)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 		 
 
 

   37   

 		 
 

   162   

 		 
 

   (77.2)   

 		 
 

   (5)   

 		 
 

   —   

 		 
 

   —   

 		 
 

   —   

 
 

  U.S.  

 		 

  4,175  

 		 
 

  4,069  

 		 
 

  2.6  

 		 
 

  —  

 		 
 

  4,167  

 		 
 

  4,046  

 		 
 

  3.0  

 		 
 
 

  8,099  

 		 
 

  7,835  

 		 
 

  3.4  

 		 
 

  —  

 		 
 

  8,083  

 		 
 

  7,787  

 		 
 

  3.8  

 
 

  Non-U.S. Developed  

 		 

  2,368  

 		 
 

  2,157  

 		 
 

  9.8  

 		 
 

  101  

 		 
 

  2,259  

 		 
 

  2,123  

 		 
 

  6.4  

 		 
 
 

  4,831  

 		 
 

  4,485  

 		 
 

  7.7  

 		 
 

  96  

 		 
 

  4,722  

 		 
 

  4,420  

 		 
 

  6.8  

 
 

  Emerging Markets  

 		 

  1,441  

 		 
 

  1,359  

 		 
 

  6.0  

 		 
 

  (17)  

 		 
 

  1,451  

 		 
 

  1,334  

 		 
 

  8.8  

 		 
 
 

  2,755  

 		 
 

  2,635  

 		 
 

  4.6  

 		 
 

  (57)  

 		 
 

  2,800  

 		 
 

  2,586  

 		 
 

  8.3  

 
 

   TOTAL   

 		 

   $    7,984   

 		 
 

   $    7,585   

 		 
 

   5.3 %   

 		 
 

   $         85   

 		 
 

   $    7,876   

 		 
 

   $    7,503   

 		 
 

   5.0 %   

 		 
 
 

   $   15,686   

 		 
 

   $   14,955   

 		 
 

   4.9 %   

 		 
 

   $         38   

 		 
 

   $   15,605   

 		 
 

   $   14,793   

 		 
 

   5.5 %   

 
 
 
 
          
 
 
 

  (1)  

 		 

  U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.  

 
 

  (2)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 

  (3)  

 		 

  The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.  

 
 

  (4)  

 		 

  Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.  

 
 
 

 

 
 
                                                                                                                                                                                        
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED STATEMENTS OF INCOME   

 
 

  (Unaudited)  

 
 
 
 

   Three months ended   

 		 
 

   Six months ended   

 
 

   (in millions, except per share data)   

 		 

   October 27,
2023   

 		 
 

   October 28,
2022   

 		 
 

   October 27,
2023   

 		 
 

   October 28,
2022   

 
 

   Net sales   

 		 

  $             7,984  

 		 
 

  $             7,585  

 		 
 

  $           15,686  

 		 
 

  $           14,955  

 
 

   Costs and expenses:   

 		 
 
 
 
 
 
 
 

  Cost of products sold, excluding amortization of intangible assets  

 		 

  2,761  

 		 
 

  2,535  

 		 
 

  5,390  

 		 
 

  5,051  

 
 

  Research and development expense  

 		 

  698  

 		 
 

  676  

 		 
 

  1,365  

 		 
 

  1,368  

 
 

  Selling, general, and administrative expense  

 		 

  2,686  

 		 
 

  2,617  

 		 
 

  5,299  

 		 
 

  5,184  

 
 

  Amortization of intangible assets  

 		 

  425  

 		 
 

  421  

 		 
 

  855  

 		 
 

  844  

 
 

  Restructuring charges, net  

 		 

  40  

 		 
 

  30  

 		 
 

  94  

 		 
 

  44  

 
 

  Certain litigation charges  

 		 

  65  

 		 
 

  —  

 		 
 

  105  

 		 
 

  —  

 
 

  Other operating income, net  

 		 

  (31)  

 		 
 

  (97)  

 		 
 

  (30)  

 		 
 

  (62)  

 
 

   Operating profit   

 		 

  1,340  

 		 
 

  1,404  

 		 
 

  2,608  

 		 
 

  2,528  

 
 

  Other non-operating income, net  

 		 

  (154)  

 		 
 

  (109)  

 		 
 

  (230)  

 		 
 

  (192)  

 
 

  Interest expense, net  

 		 

  180  

 		 
 

  118  

 		 
 

  329  

 		 
 

  282  

 
 

   Income before income taxes   

 		 

  1,313  

 		 
 

  1,395  

 		 
 

  2,510  

 		 
 

  2,438  

 
 

   Income tax provision   

 		 

  402  

 		 
 

  959  

 		 
 

  802  

 		 
 

  1,072  

 
 

   Net income   

 		 

  911  

 		 
 

  435  

 		 
 

  1,708  

 		 
 

  1,367  

 
 

   Net income attributable to noncontrolling interests   

 		 

  (2)  

 		 
 

  (8)  

 		 
 

  (8)  

 		 
 

  (10)  

 
 

   Net income attributable to Medtronic   

 		 

  $                909  

 		 
 

  $                427  

 		 
 

  $             1,700  

 		 
 

  $             1,356  

 
 

   Basic earnings per share   

 		 

  $               0.68  

 		 
 

  $               0.32  

 		 
 

  $               1.28  

 		 
 

  $               1.02  

 
 

   Diluted earnings per share   

 		 

  $               0.68  

 		 
 

  $               0.32  

 		 
 

  $               1.28  

 		 
 

  $               1.02  

 
 

   Basic weighted average shares outstanding   

 		 

  1,330.2  

 		 
 

  1,329.4  

 		 
 

  1,330.3  

 		 
 

  1,329.4  

 
 

   Diluted weighted average shares outstanding   

 		 

  1,331.9  

 		 
 

  1,332.0  

 		 
 

  1,332.8  

 		 
 

  1,333.3  

 
 
 
 
  
 
 

   The data in the schedule above has been intentionally rounded to the nearest million, and therefore, the quarterly amounts may not sum to the fiscal year-to-date amounts.   

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (1)   

 
 

  (Unaudited)  

 
 
 
 

   Three months ended October 27, 2023   

 
 

   (in millions, except per share data)   

 		 

   Net
Sales   

 		 
 

   Cost of
Products
Sold   

 		 
 

   Gross
Margin
Percent   

 		 
 

   Operating
Profit   

 		 
 

   Operating
Profit
Percent   

 		 
 

   Income
Before
Income
Taxes   

 		 
 

   Net Income
attributable
to
Medtronic   

 		 
 

   Diluted
EPS   

 		 
 

   Effective
Tax
Rate   

 
 

   GAAP   

 		 

  $  7,984  

 		 
 

  $   2,761  

 		 
 

  65.4 %  

 		 
 

  $     1,340  

 		 
 

  16.8 %  

 		 
 

  $    1,313  

 		 
 

  $          909  

 		 
 

  $     0.68  

 		 
 

  30.6 %  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Amortization of intangible assets  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  425  

 		 
 

  5.3  

 		 
 

  425  

 		 
 

  360  

 		 
 

  0.27  

 		 
 

  15.3  

 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (15)  

 		 
 

  0.2  

 		 
 

  91  

 		 
 

  1.1  

 		 
 

  91  

 		 
 

  76  

 		 
 

  0.06  

 		 
 

  17.6  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (6)  

 		 
 

  0.1  

 		 
 

  58  

 		 
 

  0.7  

 		 
 

  58  

 		 
 

  51  

 		 
 

  0.04  

 		 
 

  12.1  

 
 

  Certain litigation charges  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  65  

 		 
 

  0.8  

 		 
 

  65  

 		 
 

  50  

 		 
 

  0.04  

 		 
 

  23.1  

 
 

  (Gain)/loss on minority investments (4)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  25  

 		 
 

  21  

 		 
 

  0.02  

 		 
 

  20.0  

 
 

  Medical device regulations (5)  

 		 

  —  

 		 
 

  (21)  

 		 
 

  0.3  

 		 
 

  30  

 		 
 

  0.4  

 		 
 

  30  

 		 
 

  24  

 		 
 

  0.02  

 		 
 

  20.0  

 
 

  Certain tax adjustments, net (6)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  176  

 		 
 

  0.13  

 		 
 

  —  

 
 

   Non-GAAP   

 		 

  $  7,984  

 		 
 

  $   2,720  

 		 
 

  65.9 %  

 		 
 

  $     2,009  

 		 
 

  25.2 %  

 		 
 

  $    2,008  

 		 
 

  $       1,667  

 		 
 

  $     1.25  

 		 
 

  16.9 %  

 
 

  Currency impact  

 		 

  (85)  

 		 
 

  (65)  

 		 
 

  0.5  

 		 
 

  121  

 		 
 

  1.8  

 		 
 
 
 
 
 

  0.08  

 		 
 
 

   Currency Adjusted   

 		 

  $  7,899  

 		 
 

  $   2,655  

 		 
 

  66.4 %  

 		 
 

  $     2,130  

 		 
 

  27.0 %  

 		 
 
 
 
 
 

  $     1.33  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Three months ended October 28, 2022   

 
 

   (in millions, except per share data)   

 		 

   Net
Sales   

 		 
 

   Cost of
Products
Sold   

 		 
 

   Gross
Margin
Percent   

 		 
 

   Operating
Profit   

 		 
 

   Operating
Profit
Percent   

 		 
 

   Income
Before
Income
Taxes   

 		 
 

   Net Income
attributable
to
Medtronic   

 		 
 

   Diluted
EPS   

 		 
 

   Effective
Tax
Rate   

 
 

   GAAP   

 		 

  $  7,585  

 		 
 

  $   2,535  

 		 
 

  66.6 %  

 		 
 

  $     1,404  

 		 
 

  18.5 %  

 		 
 

  $    1,395  

 		 
 

  $          427  

 		 
 

  $     0.32  

 		 
 

  68.7 %  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Amortization of intangible assets  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  421  

 		 
 

  5.6  

 		 
 

  421  

 		 
 

  356  

 		 
 

  0.27  

 		 
 

  15.4  

 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (21)  

 		 
 

  0.3  

 		 
 

  95  

 		 
 

  1.3  

 		 
 

  95  

 		 
 

  76  

 		 
 

  0.06  

 		 
 

  20.0  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (39)  

 		 
 

  0.5  

 		 
 

  63  

 		 
 

  0.8  

 		 
 

  63  

 		 
 

  55  

 		 
 

  0.05  

 		 
 

  404.2  

 
 

  (Gain)/loss on minority investments (4)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (11)  

 		 
 

  (11)  

 		 
 

  (0.01)  

 		 
 

  —  

 
 

  Medical device regulations (5)  

 		 

  —  

 		 
 

  (22)  

 		 
 

  0.3  

 		 
 

  37  

 		 
 

  0.5  

 		 
 

  37  

 		 
 

  30  

 		 
 

  0.02  

 		 
 

  18.9  

 
 

  Certain tax adjustments, net (7)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  793  

 		 
 

  0.60  

 		 
 

  —  

 
 

   Non-GAAP   

 		 

  $  7,585  

 		 
 

  $   2,454  

 		 
 

  67.6 %  

 		 
 

  $     2,020  

 		 
 

  26.6 %  

 		 
 

  $    1,999  

 		 
 

  $       1,725  

 		 
 

  $     1.30  

 		 
 

  13.3 %  

 
 
 
 
                 
 
 
 

  See description of non-GAAP financial measures contained in the press release dated November 21, 2023.  

 
 

  (1)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.  

 
 

  (2)  

 		 

  Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.  

 
 

  (3)  

 		 

  The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the impending separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.  

 
 

  (4)  

 		 

  We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 

  (5)  

 		 

  The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.  

 
 

  (6)  

 		 

  The charge primarily relates to the establishment of a valuation allowance against certain net operating losses, and a withholding tax cost related to the impending separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.  

 
 

  (7)  

 		 

  The charge primarily relates to a $764 million reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued on August 18, 2022, on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (1)   

 
 

  (Unaudited)  

 
 
 
 

   Six months ended October 27, 2023   

 
 

   (in millions, except per share data)   

 		 

   Net
Sales   

 		 
 

   Cost of
Products
Sold   

 		 
 

   Gross
Margin
Percent   

 		 
 

   Operating
Profit   

 		 
 

   Operating
Profit
Percent   

 		 
 

   Income
Before
Income
Taxes   

 		 
 

   Net Income
attributable
to
Medtronic   

 		 
 

   Diluted
EPS   

 		 
 

   Effective
Tax
Rate   

 
 

   GAAP   

 		 

  $  15,686  

 		 
 

  $   5,390  

 		 
 

  65.6 %  

 		 
 

  $     2,608  

 		 
 

  16.6 %  

 		 
 

  $    2,510  

 		 
 

  $         1,700  

 		 
 

  $     1.28  

 		 
 

  32.0 %  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Amortization of intangible assets  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  855  

 		 
 

  5.5  

 		 
 

  855  

 		 
 

  724  

 		 
 

  0.54  

 		 
 

  15.2  

 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (30)  

 		 
 

  0.2  

 		 
 

  182  

 		 
 

  1.2  

 		 
 

  182  

 		 
 

  152  

 		 
 

  0.11  

 		 
 

  16.5  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (12)  

 		 
 

  —  

 		 
 

  107  

 		 
 

  —  

 		 
 

  107  

 		 
 

  97  

 		 
 

  0.07  

 		 
 

  9.3  

 
 

  Certain litigation charges  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  105  

 		 
 

  0.7  

 		 
 

  105  

 		 
 

  81  

 		 
 

  0.06  

 		 
 

  22.9  

 
 

  (Gain)/loss on minority investments (4)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  89  

 		 
 

  85  

 		 
 

  0.06  

 		 
 

  5.6  

 
 

  Medical device regulations (5)  

 		 

  —  

 		 
 

  (42)  

 		 
 

  0.3  

 		 
 

  62  

 		 
 

  0.4  

 		 
 

  62  

 		 
 

  49  

 		 
 

  0.04  

 		 
 

  21.0  

 
 

  Certain tax adjustments, net (6)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  375  

 		 
 

  0.28  

 		 
 

  —  

 
 

   Non-GAAP   

 		 

  $  15,686  

 		 
 

  $   5,306  

 		 
 

  66.2 %  

 		 
 

  $     3,919  

 		 
 

  25.0 %  

 		 
 

  $    3,910  

 		 
 

  $         3,262  

 		 
 

  $     2.45  

 		 
 

  16.4 %  

 
 

  Currency impact  

 		 

  (38)  

 		 
 

  (66)  

 		 
 

  0.3  

 		 
 

  243  

 		 
 

  1.6  

 		 
 
 
 
 
 

  0.16  

 		 
 
 

   Currency Adjusted   

 		 

  $  15,648  

 		 
 

  $   5,240  

 		 
 

  66.5 %  

 		 
 

  $     4,162  

 		 
 

  26.6 %  

 		 
 
 
 
 
 

  $     2.61  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Six month ended October 28, 2022   

 
 

   (in millions, except per share data)   

 		 

   Net
Sales   

 		 
 

   Cost of
Products
Sold   

 		 
 

   Gross
Margin
Percent   

 		 
 

   Operating
Profit   

 		 
 

   Operating
Profit
Percent   

 		 
 

   Income
Before
Income
Taxes   

 		 
 

   Net Income
attributable
to
Medtronic   

 		 
 

   Diluted
EPS   

 		 
 

   Effective
Tax
Rate   

 
 

   GAAP   

 		 

  $  14,955  

 		 
 

  $   5,051  

 		 
 

  66.2 %  

 		 
 

  $     2,528  

 		 
 

  16.9 %  

 		 
 

  $    2,438  

 		 
 

  $         1,356  

 		 
 

  $     1.02  

 		 
 

  44.0 %  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Amortization of intangible assets  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  844  

 		 
 

  5.6  

 		 
 

  844  

 		 
 

  715  

 		 
 

  0.54  

 		 
 

  15.3  

 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (41)  

 		 
 

  0.3  

 		 
 

  171  

 		 
 

  1.1  

 		 
 

  171  

 		 
 

  136  

 		 
 

  0.10  

 		 
 

  20.5  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (50)  

 		 
 

  0.3  

 		 
 

  174  

 		 
 

  1.2  

 		 
 

  174  

 		 
 

  157  

 		 
 

  0.12  

 		 
 

  38.8  

 
 

  (Gain)/loss on minority investments (4)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (15)  

 		 
 

  (15)  

 		 
 

  (0.01)  

 		 
 

  —  

 
 

  Medical device regulations (5)  

 		 

  —  

 		 
 

  (40)  

 		 
 

  0.3  

 		 
 

  70  

 		 
 

  0.5  

 		 
 

  70  

 		 
 

  56  

 		 
 

  0.04  

 		 
 

  20.0  

 
 

  Debt redemption premium and other charges (7)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  53  

 		 
 

  42  

 		 
 

  0.03  

 		 
 

  20.8  

 
 

  Certain tax adjustments, net (8)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  780  

 		 
 

  0.59  

 		 
 

  —  

 
 

   Non-GAAP   

 		 

  $  14,955  

 		 
 

  $   4,921  

 		 
 

  67.1 %  

 		 
 

  $     3,785  

 		 
 

  25.3 %  

 		 
 

  $    3,733  

 		 
 

  $         3,226  

 		 
 

  $     2.42  

 		 
 

  13.3 %  

 
 
 
 
                   
 
 
 

  See description of non-GAAP financial measures contained in the press release dated November 21, 2023.  

 
 

  (1)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.  

 
 

  (2)  

 		 

  Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.  

 
 

  (3)  

 		 

  The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the impending separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio. The prior year included non-cash pre-tax impairments, primarily related to goodwill and other associated costs, as a result of the April 1, 2023, sale of half of the Company's Renal Care Solutions (RCS) business.  

 
 

  (4)  

 		 

  We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 

  (5)  

 		 

  The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific period.  

 
 

  (6)  

 		 

  The charge relates to an income tax reserve adjustment associated with the June 1, 2023, Israeli Central-Lod District Court decision, the establishment of a valuation allowance against certain net operating losses, a withholding tax cost related to the impending separation of the Patient Monitoring and Respiratory Interventions businesses, and amortization of previously established deferred tax assets from intercompany intellectual property transactions.  

 
 

  (7)  

 		 

  The charges relate to the early redemption of approximately $2.3 billion of debt and were recorded within interest expense, net within the consolidated statements of income.  

 
 

  (8)  

 		 

  The charge primarily relates to a $764 million reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued on August 18, 2022, on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                         
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (1)   

 
 

  (Unaudited)  

 
 
 
 

   Three months ended October 27, 2023   

 
 

   (in millions)   

 		 

   Net Sales   

 		 
 

   SG&A
Expense   

 		 
 

   SG&A
Expense as
a % of Net
Sales   

 		 
 

   R&D
Expense   

 		 
 

   R&D
Expense
as a % of
Net Sales   

 		 
 

   Other
Operating
(Income)
Expense,
net   

 		 
 

   Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales   

 		 
 

   Other Non-
Operating
Income, net   

 
 

   GAAP   

 		 

  $      7,984  

 		 
 

  $     2,686  

 		 
 

  33.6 %  

 		 
 

  $       698  

 		 
 

  8.7 %  

 		 
 

  $         (31)  

 		 
 

  (0.4) %  

 		 
 

  $          (154)  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (36)  

 		 
 

  (0.5)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (26)  

 		 
 

  (0.3)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (26)  

 		 
 

  (0.3)  

 		 
 

  —  

 
 

  Medical device regulations (4)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (9)  

 		 
 

  (0.1)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

  (Gain)/loss on minority investments (5)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (25)  

 
 

   Non-GAAP   

 		 

  $      7,984  

 		 
 

  $     2,623  

 		 
 

  32.9 %  

 		 
 

  $       688  

 		 
 

  8.6 %  

 		 
 

  $         (57)  

 		 
 

  (0.7) %  

 		 
 

  $          (179)  

 
 

  Currency impact  

 		 

  (85)  

 		 
 

  (36)  

 		 
 

  (0.1)  

 		 
 

  (1)  

 		 
 

  0.1  

 		 
 

  (104)  

 		 
 

  (1.3)  

 		 
 

  4  

 
 

   Currency Adjusted   

 		 

  $      7,899  

 		 
 

  $     2,587  

 		 
 

  32.8 %  

 		 
 

  $       687  

 		 
 

  8.7 %  

 		 
 

  $       (161)  

 		 
 

  (2.0) %  

 		 
 

  $          (175)  

 
 
 
 

   Six months ended October 27, 2023   

 
 

   (in millions)   

 		 

   Net Sales   

 		 
 

   SG&A
Expense   

 		 
 

   SG&A
Expense as
a % of Net
Sales   

 		 
 

   R&D
Expense   

 		 
 

   R&D
Expense
as a % of
Net Sales   

 		 
 

   Other
Operating
(Income)
Expense,
net   

 		 
 

   Other Operating
(Inc.)/Exp.,
net as a % of
Net Sales   

 		 
 

   Other Non-
Operating
Income, net   

 
 

   GAAP   

 		 

  $    15,686  

 		 
 

  $     5,299  

 		 
 

  33.8 %  

 		 
 

  $    1,365  

 		 
 

  8.7 %  

 		 
 

  $         (30)  

 		 
 

  (0.2) %  

 		 
 

  $          (230)  

 
 

  Non-GAAP Adjustments:  

 		 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (2)  

 		 

  —  

 		 
 

  (57)  

 		 
 

  (0.4)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  1  

 		 
 

  —  

 		 
 

  —  

 
 

  Acquisition and divestiture-related items (3)  

 		 

  —  

 		 
 

  (42)  

 		 
 

  (0.3)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (53)  

 		 
 

  (0.3)  

 		 
 

  —  

 
 

  Medical device regulations (4)  

 		 

  —  

 		 
 

  (1)  

 		 
 

  —  

 		 
 

  (19)  

 		 
 

  (0.1)  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 
 

  (Gain)/loss on minority investments (5)  

 		 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  —  

 		 
 

  (89)  

 
 

   Non-GAAP   

 		 

  $    15,686  

 		 
 

  $     5,199  

 		 
 

  33.1 %  

 		 
 

  $    1,346  

 		 
 

  8.6 %  

 		 
 

  $         (83)  

 		 
 

  (0.5) %  

 		 
 

  $          (320)  

 
 

  Currency impact  

 		 

  (38)  

 		 
 

  (31)  

 		 
 

  (0.1)  

 		 
 

  2  

 		 
 

  —  

 		 
 

  (186)  

 		 
 

  (1.2)  

 		 
 

  5  

 
 

   Currency Adjusted   

 		 

  $    15,648  

 		 
 

  $     5,168  

 		 
 

  33.0 %  

 		 
 

  $    1,348  

 		 
 

  8.6 %  

 		 
 

  $       (269)  

 		 
 

  (1.7) %  

 		 
 

  $          (315)  

 
 
 
 
             
 
 
 

  See description of non-GAAP financial measures contained in the press release dated November 21, 2023.  

 
 

  (1)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.  

 
 

  (2)  

 		 

  Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.  

 
 

  (3)  

 		 

  The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the impending separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.  

 
 

  (4)  

 		 

  The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.  

 
 

  (5)  

 		 

  We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 
 

 

 
 
                      
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (1)   

 
 

  (Unaudited)  

 
 
 
 

   Six months ended   

 
 

   (in millions)   

 		 

   October 27, 2023   

 		 
 

   October 28, 2022   

 
 

   Net cash provided by operating activities   

 		 

  $                      1,536  

 		 
 

  $                      2,005  

 
 

  Additions to property, plant, and equipment  

 		 

  (815)  

 		 
 

  (749)  

 
 

   Free Cash Flow (2)   

 		 

  $                         721  

 		 
 

  $                      1,256  

 
 
 
 
      
 
 

  See description of non-GAAP financial measures contained in the press release dated November 21, 2023.  

 
 

  (1)  

 		 

  The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.  

 
 

  (2)  

 		 

  Free cash flow represents operating cash flows less property, plant, and equipment additions.  

 
 
 

 

 
 
                                                                                                                                                                                                       
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED BALANCE SHEETS   

 
 

   (Unaudited)   

 
 
 

   (in millions)   

 		 
 

   October 27, 2023   

 		 
 

   April 28, 2023   

 
 

    ASSETS    

 		 
 
 
 
 

   Current assets:   

 		 
 
 
 
 

  Cash and cash equivalents  

 		 
 

  $               1,311  

 		 
 

  $               1,543  

 
 

  Investments  

 		 
 

  6,423  

 		 
 

  6,416  

 
 

  Accounts receivable, less allowances and credit losses of $177 and $176, respectively  

 		 
 

  5,934  

 		 
 

  5,998  

 
 

  Inventories, net  

 		 
 

  5,754  

 		 
 

  5,293  

 
 

  Other current assets  

 		 
 

  2,658  

 		 
 

  2,425  

 
 

   Total current assets   

 		 
 

  22,081  

 		 
 

  21,675  

 
 

   Property, plant, and equipment, net   

 		 
 

  5,735  

 		 
 

  5,569  

 
 

   Goodwill   

 		 
 

  40,821  

 		 
 

  41,425  

 
 

   Other intangible assets, net   

 		 
 

  14,060  

 		 
 

  14,844  

 
 

   Tax assets   

 		 
 

  3,428  

 		 
 

  3,477  

 
 

   Other assets   

 		 
 

  3,962  

 		 
 

  3,959  

 
 

   Total assets   

 		 
 

  $             90,087  

 		 
 

  $             90,948  

 
 

    LIABILITIES AND EQUITY    

 		 
 
 
 
 

   Current liabilities:   

 		 
 
 
 
 

  Current debt obligations  

 		 
 

  $               1,339  

 		 
 

  $                     20  

 
 

  Accounts payable  

 		 
 

  2,174  

 		 
 

  2,662  

 
 

  Accrued compensation  

 		 
 

  1,758  

 		 
 

  1,949  

 
 

  Accrued income taxes  

 		 
 

  1,088  

 		 
 

  840  

 
 

  Other accrued expenses  

 		 
 

  3,299  

 		 
 

  3,581  

 
 

   Total current liabilities   

 		 
 

  9,659  

 		 
 

  9,051  

 
 

   Long-term debt   

 		 
 

  23,741  

 		 
 

  24,344  

 
 

   Accrued compensation and retirement benefits   

 		 
 

  1,020  

 		 
 

  1,093  

 
 

   Accrued income taxes   

 		 
 

  1,777  

 		 
 

  2,360  

 
 

   Deferred tax liabilities   

 		 
 

  686  

 		 
 

  708  

 
 

   Other liabilities   

 		 
 

  1,556  

 		 
 

  1,727  

 
 

   Total liabilities   

 		 
 

  38,440  

 		 
 

  39,283  

 
 

   Commitments and contingencies   

 		 
 
 
 
 

   Shareholders' equity:   

 		 
 
 
 
 

  Ordinary shares— par value $0.0001, 2.6 billion shares authorized,
1,330,173,450 and 1,330,809,036 shares issued and outstanding, respectively  

 		 
 

  —  

 		 
 

  —  

 
 

  Additional paid-in capital  

 		 
 

  24,580  

 		 
 

  24,590  

 
 

  Retained earnings  

 		 
 

  30,256  

 		 
 

  30,392  

 
 

  Accumulated other comprehensive loss  

 		 
 

  (3,377)  

 		 
 

  (3,499)  

 
 

   Total shareholders' equity   

 		 
 

  51,460  

 		 
 

  51,483  

 
 

  Noncontrolling interests  

 		 
 

  187  

 		 
 

  182  

 
 

   Total equity   

 		 
 

  51,647  

 		 
 

  51,665  

 
 

   Total liabilities and equity   

 		 
 

  $             90,087  

 		 
 

  $             90,948  

 
 
 
 
  
 
 

   The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.   

 
 
 

 

 
 
                                                                                                                                                                          
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED STATEMENTS OF CASH FLOWS   

 
 

  (Unaudited)  

 
 
 
 

   Six months ended   

 
 

   (in millions)   

 		 

   October 27, 2023   

 		 
 

   October 28, 2022   

 
 

   Operating Activities:   

 		 
 
 
 

  Net income  

 		 

  $                1,708  

 		 
 

  $                1,367  

 
 

  Adjustments to reconcile net income to net cash provided by operating activities:  

 		 
 
 
 

  Depreciation and amortization  

 		 

  1,344  

 		 
 

  1,339  

 
 

  Provision for credit losses  

 		 

  37  

 		 
 

  41  

 
 

  Deferred income taxes  

 		 

  (36)  

 		 
 

  (92)  

 
 

  Stock-based compensation  

 		 

  219  

 		 
 

  199  

 
 

  Loss on debt extinguishment  

 		 

  —  

 		 
 

  53  

 
 

  Other, net  

 		 

  182  

 		 
 

  148  

 
 

  Change in operating assets and liabilities, net of acquisitions and divestitures:  

 		 
 
 
 

  Accounts receivable, net  

 		 

  (117)  

 		 
 

  (346)  

 
 

  Inventories, net  

 		 

  (616)  

 		 
 

  (784)  

 
 

  Accounts payable and accrued liabilities  

 		 

  (699)  

 		 
 

  (14)  

 
 

  Other operating assets and liabilities  

 		 

  (486)  

 		 
 

  94  

 
 

   Net cash provided by operating activities   

 		 

  1,536  

 		 
 

  2,005  

 
 

   Investing Activities:   

 		 
 
 
 

  Acquisitions, net of cash acquired  

 		 

  (22)  

 		 
 

  (1,867)  

 
 

  Additions to property, plant, and equipment  

 		 

  (815)  

 		 
 

  (749)  

 
 

  Purchases of investments  

 		 

  (3,403)  

 		 
 

  (3,743)  

 
 

  Sales and maturities of investments  

 		 

  3,336  

 		 
 

  3,609  

 
 

  Other investing activities, net  

 		 

  (59)  

 		 
 

  19  

 
 

   Net cash used in investing activities   

 		 

  (963)  

 		 
 

  (2,731)  

 
 

   Financing Activities:   

 		 
 
 
 

  Change in current debt obligations, net  

 		 

  1,321  

 		 
 

  349  

 
 

  Proceeds from short-term borrowings (maturities greater than 90 days)  

 		 

  —  

 		 
 

  2,284  

 
 

  Issuance of long-term debt  

 		 

  —  

 		 
 

  3,430  

 
 

  Payments on long-term debt  

 		 

  —  

 		 
 

  (2,311)  

 
 

  Dividends to shareholders  

 		 

  (1,836)  

 		 
 

  (1,807)  

 
 

  Issuance of ordinary shares  

 		 

  149  

 		 
 

  153  

 
 

  Repurchase of ordinary shares  

 		 

  (378)  

 		 
 

  (477)  

 
 

  Other financing activities  

 		 

  153  

 		 
 

  443  

 
 

   Net cash (used in) provided by financing activities   

 		 

  (591)  

 		 
 

  2,064  

 
 

  Effect of exchange rate changes on cash and cash equivalents  

 		 

  (214)  

 		 
 

  (223)  

 
 

   Net change in cash and cash equivalents   

 		 

  (232)  

 		 
 

  1,114  

 
 

  Cash and cash equivalents at beginning of period  

 		 

  1,543  

 		 
 

  3,714  

 
 

   Cash and cash equivalents at end of period   

 		 

  $                1,311  

 		 
 

  $                4,828  

 
 

   Supplemental Cash Flow Information   

 		 
 
 
 

  Cash paid for:  

 		 
 
 
 

  Income taxes  

 		 

  $                1,110  

 		 
 

  $                   821  

 
 

  Interest  

 		 

  476  

 		 
 

  234  

 
 
 
 
  
 
 

   The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.   

 
 
 

 

 

   About Medtronic
  Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on X (formerly Twitter) and LinkedIn .

 

   FORWARD LOOKING STATEMENTS
   This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.  

 

   NON-GAAP FINANCIAL MEASURES
   This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2023.  

 

  Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.  

 

  Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.  

 
 
          
 

   Contacts:   

 		 
 
 
 

  Erika Winkels  

 		 

  Ryan Weispfenning  

 
 

  Public Relations  

 		 

  Investor Relations  

 
 

  +1-763-526-8478  

 		 

  +1-763-505-4626  

 
 
 

 

 
 

   

 
 

 

 
 

   

 

  

 

  (PRNewsfoto/Medtronic plc) 

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-second-quarter-fiscal-2024-financial-results-301994289.html  

 

SOURCE Medtronic plc

 
 

News Provided by PR Newswire via QuoteMedia

medical device investing
MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

 

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

 

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

 

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

 

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

 
 

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

 
 

  2024 ATCO AGM (CNW Group/ATCO Ltd.) 

 

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

 

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

 

Attendees will hear from:

 
  •    Nancy Southern , Chair & Chief Executive Officer  
    •  
  •    Katie Patrick , Executive Vice President, Chief Financial & Investment Officer  
    •  
  •    Adam Beattie , President, ATCO Structures  
    •  
  •    Bob Myles , Chief Operating Officer, ATCO EnPower  
    •  
  •    Wayne Stensby , Chief Operating Officer, ATCO Energy Systems  
    •  

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

 

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

 

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

 

  Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
  Colin.Jackson@atco.com   
(403) 808 2636

 

  Media Inquiries:
  Kurt Kadatz  
Director, Corporate Communications
  Kurt.Kadatz@atco.com   
(587) 228 4571

 

SOURCE ATCO Ltd.

 

 

 

 Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html  

 
 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

 

-

 

 PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest News

More News

Latest Press Releases

Pinnacle Increases Non-Brokered Private Placement

Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

Quarterly Activities/Appendix 5B Cash Flow Report

Related News

copper investing

Top 5 Canadian Mining Stocks This Week: St. Augustine Gains 67 Percent

Vanadium Investing

Top 5 Australian Mining Stocks This Week: Vanadium Resources Soars on DSO Offtake Deal

Copper Investing

Editor's Picks: Miners Rescued, US Mine Waste Strategy, Ontario Expands CIMF

Precious Metals Investing

Pinnacle Increases Non-Brokered Private Placement

copper investing

Teck Greenlights Highland Valley Expansion After Beating Q2 Profit Estimates

Base Metals Investing

Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

Precious Metals Investing

Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

×